DNTGF-βR armored CAR-T cell therapy against tumors from bench to bedside
Y Wang, G Zhao, S Wang, N Li - Journal of Translational Medicine, 2024 - Springer
CAR-T cell therapy has achieved great success in hematological malignancies, but its
effectiveness in solid tumors has been limited due to the complicated immunosuppressive …
effectiveness in solid tumors has been limited due to the complicated immunosuppressive …
Blood cancer therapy with synthetic receptors and CRISPR technology
H Zhang, M Zhong, J Zhang, C Chen - Leukemia Research, 2025 - Elsevier
Chimeric antigen receptor (CAR)-T and-NK cells showed great success in treating
hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR …
hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR …
Sialylation-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in uterine …
J Chen, T Wu, Y Yang - Cancer Cell International, 2024 - Springer
Background Sialylation in uterine corpus endometrial carcinoma (UCEC) differs significantly
from apoptotic and ferroptosis pathways. It plays a crucial role in cancer progression and …
from apoptotic and ferroptosis pathways. It plays a crucial role in cancer progression and …
Improving adoptive T cell therapy by positive conversion of negative signaling
JQ Liu, B Zhao, CH Lin, XF Bai - T Cell Metabolism and Cancer …, 2025 - Elsevier
Adoptive T cell transfer therapy (ACT) is an emerging cancer treatment that involves
expanding tumor-infiltrating T lymphocytes (TILs) or harvesting and genetically modifying a …
expanding tumor-infiltrating T lymphocytes (TILs) or harvesting and genetically modifying a …
Coagulation factor II thrombin receptor as a promising biomarker in breast cancer management
YM Dong, GQ Bao - Open Life Sciences, 2024 - degruyter.com
This study aims to comprehensively investigate the role of coagulation factor II thrombin
receptor (F2R) in breast cancer (BC) and to evaluate its potential as a biomarker in this …
receptor (F2R) in breast cancer (BC) and to evaluate its potential as a biomarker in this …
Mécanismes d'action et de résistance aux cellules T à récepteur antigénique chimérique dans les hémopathies B matures
J Ferrant, K Tarte - Hématologie, 2024 - stm.cairn.info
1 Malgré les immenses progrès apportés en hématologie, depuis une vingtaine d'années,
par l'avènement de l'immunochimiothérapie, de nombreux patients restent réfractaires au …
par l'avènement de l'immunochimiothérapie, de nombreux patients restent réfractaires au …